Stock Price Quote

SUVEN LIFE SCIENCES LTD.

NSE : SUVENBSE : 530239ISIN CODE : INE495B01038Industry : Pharmaceuticals & DrugsHouse : Private
BSE188.005.8 (+3.18 %)
PREV CLOSE ( ) 182.20
OPEN PRICE ( ) 182.20
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 41509
TODAY'S LOW / HIGH ( )182.00 190.35
52 WK LOW / HIGH ( )102.7 303
NSE188.025.6 (+3.07 %)
PREV CLOSE( ) 182.42
OPEN PRICE ( ) 182.00
BID PRICE (QTY) 188.02 (12)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 161414
TODAY'S LOW / HIGH( ) 182.00 192.00
52 WK LOW / HIGH ( )102.5 299.99
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 09-03 1989
Management Info
Venkateswarlu Jasti - Chairman Venkateswarlu Jasti - Managing Director
Registered Office

Address 8-2-334, S D E Serene Chambers,6th Floor, Road No 5, Avenue 7,Banjara Hills,
Hyderabad,
Telangana-500034

Phone 040- 23541142 /3315 / 23543311

Email info@suven.com

Website www.suven.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

03Nov Suven Life Sciences informs about boa
Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Re..
03Jul Suven Life Sciences informs about outc
Suven Life Sciences has informed that the Board of Directors of the Comp..
05Jun Suven Life Sciences informs about disc
With reference to earlier letters dated 14th May, 2025, 28th May, 2025 a..
13May Suven Life Sciences informs about outc
Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulatio..
12May Suven Pharmaceuticals informs about di
Suven Pharmaceuticals has informed that the exchange has received Disclo..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit-154.45-470.8
Gross Profit -154.45 -470.8
Operating Profit -141.28-412.11
Net Sales 9.1966.56

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  17550.00 (2.03%)
M.Cap ( in Cr)22389.38
Alkem Laboratories (BSE)
peergroup  5787.70 (1.52%)
M.Cap ( in Cr)68496.40
Astrazeneca Pharma I (BSE)
peergroup  9212.95 (0.89%)
M.Cap ( in Cr)23146.13
Lupin (BSE)
peergroup  2035.85 (3.04%)
M.Cap ( in Cr)91809.20
Mankind Pharma (BSE)
peergroup  2280.20 (2.70%)
M.Cap ( in Cr)92870.66

Shareholding Pattern

PROMOTERS 67.36%
NON-INSTITUTION 28.07%
MUTUAL FUNDS/UTI 2.08%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Suven Life Sciences Ltd.

Suven Life Sciences Ltd. was incorporated in the year 1989. Its today's share price is 188. Its current market capitalisation stands at Rs 4276.52 Cr. In the latest quarter, company has reported Gross Sales of Rs. 66.56 Cr and Total Income of Rs.173.82 Cr. The company's management includes Sudha Rani Jasti, Shrenik Soni, Vajja Sambasiva Rao, JAS Padmaja, Santanu Mukherjee, Seyed E Hasnain, Venkateswarlu Jasti, Venkateswarlu Jasti.

It is listed on the BSE with a BSE Code of 530239 , NSE with an NSE Symbol of SUVEN and ISIN of INE495B01038. It's Registered office is at 8-2-334, S D E Serene Chambers,6th Floor, Road No 5, Avenue 7,Banjara HillsHyderabad-500034, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Karvy & Co, Tukaram & Co, Tukaram & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.